الصفحة الرئيسية>>Signaling Pathways>> Neuroscience>> Histamine Receptor>>Mebhydrolin napadisylate (Mebhydroline 1,5-naphthalenedisulfonate salt)

Mebhydrolin napadisylate (Mebhydroline 1,5-naphthalenedisulfonate salt)

رقم الكتالوجGC31848

Mebhydrolin napadisylate (ملح Mebhydroline 1،5-naphthalenedisulfonate) هو مضاد محدد لمستقبلات الهيستامين H1.

Products are for research use only. Not for human use. We do not sell to patients.

Mebhydrolin napadisylate (Mebhydroline 1,5-naphthalenedisulfonate salt) التركيب الكيميائي

Cas No.: 6153-33-9

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
50٫00
متوفر
100mg
46٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Mebhydrolin napadisylate is a specific histamine H1 receptor antagonist.

Mebhydrolin is a specific histamine H1-receptor antagonist with minimal sedative properties and comparing it with the effects of chlorpromazine, the archetypical phenothiazine[1]. Mebhydrolin exerts an antihistaminic effect over the period of the ethanol interaction study[2].

[1]. O'Neill PA, et al. Chlorpromazine-a specific effect on breathlessness? Br J Clin Pharmacol. 1985 Jun;19(6):793-7. [2]. Franks HM, et al. Interaction between ethanol and antihistamines: 3. Mebhydrolin. Med J Aust. 1981 Oct 31;2(9):477-9.

مراجعات

Review for Mebhydrolin napadisylate (Mebhydroline 1,5-naphthalenedisulfonate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 28 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Mebhydrolin napadisylate (Mebhydroline 1,5-naphthalenedisulfonate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.